Text and Data Mining valid from 2019-05-10
Received: 22 August 2018
Accepted: 17 April 2019
First Online: 10 May 2019
Ethics approval and consent to participate
: GeparQuinto study:Registration number: Decemeber 04 2007 Ethics commission of the special field “Medicine” at the Goethe University Frankfurt, GermanyEudraCT number: 2006-005834-19Date of registration: April 12, 2007GeparSixto study:Registration number: 2011154Ethics commission of the Medical Association (Aerztekammer) Nordrhein, GermanyEudraCT number: G6: 2011-000553-23Date of registration: August 17, 2011
: Not applicable
: Volkmar Müller has received speaker honoraria from Amgen, Astra Zeneca, Daiichi-Sankyo, Eisai, Pfizer, Novartis, Roche, Teva, and Tesaro; consultancy honoraria from Hexal, Roche, Pfizer, Amgen, Daiichi-Sankyo, Nektar, and Eisai; and travel funding from Roche and Pfizer.Claus Hanusch has received honoraria from Roche, Amgen, and Novartis.The presented subanalysis was not funded. The GeparQuinto study was funded by GlaxoSmithKline, Novartis Pharma, Roche Pharma, and Sanofi-Aventis. The GeparSixto study was funded by Cephalon, Roche Pharma, and GlaxoSmithKline. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.